STATEMENT RE COHERUS BIOSCIENCES, INC.
BioPharma Credit PLC
10 May 2024
BIOPHARMA CREDIT PLC
(THE "COMPANY")
STATEMENT RE Coherus BIOSCIENCES, Inc.
Pharmakon Advisors, LP, the investment manager of the Company, notes the announcement released 9 May 2024 by Coherus Biosciences, Inc. ("Coherus") regarding entering into a combined term loan and product royalty financing agreement with Barings (the "New Financing"). The New Financing allowed Coherus to fully pay off its remaining USD$75 million senior secured term loan, of which the Company had an investment of USD$37.5 million.
The Company had previously announced on 10 January 2022 an investment in a senior secured loan to Coherus of up to USD$150 million in up to three tranches. The Company had previously funded US$125 million, of which USD$87.5 million was repaid as referenced in the Company's announcement on 6 February 2024. The remaining USD$37.5 million was repaid to the Company in connection with the New Financing. In connection with this final repayment, the Company received US$39.8 million in total, including USD$2.3 million of accrued interest, and prepayment and make-whole fees.
Enquiries:
BioPharma Credit plc
via Link Company Matters Limited
Company Secretary
+44 (0)1392 477 509
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
COMPANIES COVERED:
Latest directors dealings
- 4 hours ago Aquila Energy Efficiency Trust (EUR)
- 4 hours ago Boohoo Group
- 4 hours ago Tritax Big Box Reit
- 5 hours ago Standard Chartered
- 5 hours ago Coca-Cola HBC AG (CDI)